CGT Catapult boost for UK life science campus

By Rachel Arthur

- Last updated on GMT

Pic:getty/totojang
Pic:getty/totojang

Related tags Cell therapy cell and gene therapy Gene therapy

The Cell and Gene Therapy Catapult (CGT Catapult) has confirmed its involvement in the development of a new £900m ($1,097m) life science campus in Stevenage, UK: which is set to become one of the largest in Europe.

Announced last year, the new life science campus will be built alongside the Stevenage Bioscience Catalyst – an organization which provides a supportive environment for companies to develop and commercialize advanced therapeutics– and GSK’s existing Global R&D center. It is expected to cover around 1.4 million square feet of laboratory and office facilities with space for up to 5,000 new jobs.

The campus, which is backed by UBS Asset Management and Reef, intends to help meet the growing demand for state-of-the-art commercial and laboratory space from both emerging and established life science firms.

The CGT Catapult is an independent innovation and technology organization committed to advancing cell and gene therapies, which works with government agency Innovate UK.

“The Catapult has already played a significant role in establishing the largest cell and gene therapy cluster in Europe in the UK, centred on its Manufacturing Innovation Centre (MIC) in Stevenage," says the organization.

"The MHRA licensed Stevenage MIC, which incorporates 12 segregated independent GMP cleanroom modules, was established in 2018 and has excellent international connectivity and supply chain links, an optimum skills base and a supportive environment for collaborators to grow.

“This latest agreement will ensure that the CGT Catapult remains within the Stevenage campus and also provides the potential for further expansion of its development, manufacturing and skills facilities in order to continue to drive innovation and growth in both the Stevenage cluster and the UK advanced therapy sector as a whole.”  

Related topics Bio Developments

Related news

Show more

Follow us

Webinars

Headlines